Warburg Pincus (Cayman) China-Southeast Asia II GP LLC - Net Worth and Insider Trading

Warburg Pincus (Cayman) China-Southeast Asia II GP LLC Net Worth

The estimated net worth of Warburg Pincus (Cayman) China-Southeast Asia II GP LLC is at least $70 Million dollars as of 2025-06-11. Warburg Pincus (Cayman) China-Southeast Asia II GP LLC is the 2201 Interest of corporation controlled by you of Gaush Meditech Ltd and owns about 11,375,840 shares of Gaush Meditech Ltd (HKSE:02407) stock worth over $70 Million. Details can be seen in Warburg Pincus (Cayman) China-Southeast Asia II GP LLC's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Warburg Pincus (Cayman) China-Southeast Asia II GP LLC has not made any transactions after 2022-12-12 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.

Transaction Summary of Warburg Pincus (Cayman) China-Southeast Asia II GP LLC

Warburg Pincus (Cayman) China-Southeast Asia II GP LLC Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Warburg Pincus (Cayman) China-Southeast Asia II GP LLC owns 1 companies in total, including Gaush Meditech Ltd (HKSE:02407) .

Click here to see the complete history of Warburg Pincus (Cayman) China-Southeast Asia II GP LLC’s form 4 insider trades.

Insider Ownership Summary of Warburg Pincus (Cayman) China-Southeast Asia II GP LLC

Ticker	Company	Transaction Date	Type of Owner
HKSE:02407	Gaush Meditech Ltd	2022-12-12	2201 Interest of corporation controlled by you

Warburg Pincus (Cayman) China-Southeast Asia II GP LLC Latest Holdings Summary

Warburg Pincus (Cayman) China-Southeast Asia II GP LLC currently owns a total of 1 stock. Warburg Pincus (Cayman) China-Southeast Asia II GP LLC owns 11,375,840 shares of Gaush Meditech Ltd (HKSE:02407) as of December 12, 2022, with a value of $70 Million.

Latest Holdings of Warburg Pincus (Cayman) China-Southeast Asia II GP LLC

Ticker	Company	Latest Transaction Date	Shares Owned	Current Price ($)	Current Value ($)
HKSE:02407	Gaush Meditech Ltd	2022-12-12	11,375,840	6.16	70,075,174

Holding Weightings of Warburg Pincus (Cayman) China-Southeast Asia II GP LLC

Warburg Pincus (Cayman) China-Southeast Asia II GP LLC Form 4 Trading Tracker

According to the SEC Form 4 filings, Warburg Pincus (Cayman) China-Southeast Asia II GP LLC has made a total of 1 transactions in Gaush Meditech Ltd (HKSE:02407) over the past 5 years, including 0 buys and 0 sells. The most-recent trade in Gaush Meditech Ltd is the sale of 11,375,840 shares on December 12, 2022, which brought Warburg Pincus (Cayman) China-Southeast Asia II GP LLC around $0.

Insider Trading History of Warburg Pincus (Cayman) China-Southeast Asia II GP LLC

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.

Total 0

Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Warburg Pincus (Cayman) China-Southeast Asia II GP LLC Trading Performance

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Warburg Pincus (Cayman) China-Southeast Asia II GP LLC Ownership Network

Ownership Network List of Warburg Pincus (Cayman) China-Southeast Asia II GP LLC

No Data

Ownership Network Relation of Warburg Pincus (Cayman) China-Southeast Asia II GP LLC

Warburg Pincus (Cayman) China-Southeast Asia II GP LLC Owned Company Details

What does Gaush Meditech Ltd do?

Who are the key executives at Gaush Meditech Ltd?

Warburg Pincus (Cayman) China-Southeast Asia II GP LLC is the 2201 Interest of corporation controlled by you of Gaush Meditech Ltd. Other key executives at Gaush Meditech Ltd include 2102 Investment manager OrbiMed Advisors III Limited , 2102 Investment manager OrbiMed Asia GP III, L.P. , and 2102 Investment manager OrbiMed Asia Partners III, L.P. .

Gaush Meditech Ltd (HKSE:02407) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Gaush Meditech Ltd (HKSE:02407) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Gaush Meditech Ltd (HKSE:02407) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Gaush Meditech Ltd (HKSE:02407)'s detailed insider trading history can be found in Insider Trading Tracker table.

Gaush Meditech Ltd Insider Transactions

No Available Data

Warburg Pincus (Cayman) China-Southeast Asia II GP LLC Mailing Address

Above is the net worth, insider trading, and ownership report for Warburg Pincus (Cayman) China-Southeast Asia II GP LLC. Currently GuruFocus does not have mailing address information for Warburg Pincus (Cayman) China-Southeast Asia II GP LLC.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.